Vanguard Capital Management
CRL icon

Vanguard Capital Management’s Charles River Laboratories CRL Stock Holding History

Vanguard Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$714M Sell
3,149,288
-52,916
-2% -$9.42M 0.02% 592
2026
Q1 		$552M Buy
+3,202,204
New +$594M 0.01% 636

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management's CRL Position: Q2 2026 in Review

Vanguard Capital Management reduced its Charles River Laboratories (CRL) stake by 1.7% in Q2 2026, selling an estimated $9.42M and leaving 3,149,288 shares worth $714M. The position accounts for 0.02% of the portfolio, ranked #592.

Vanguard Capital Management first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 531 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Vanguard Capital Management held 3,149,288 shares of Charles River Laboratories worth $714M as of Q2 2026.
  • Vanguard Capital Management sold 52,916 Charles River Laboratories shares in Q2 2026, an estimated $9.42M.
  • Charles River Laboratories made up 0.02% of Vanguard Capital Management's portfolio in Q2 2026, its #592 holding.
  • Vanguard Capital Management first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
  • 531 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.